Amarin's (AMRN) Vascepa on Way to Blockbuster Drug Status - Aegis Capital
Tweet Send to a Friend
Aegis Capital analyst Nathan Weinstein reiterated a Buy rating and $23.00 price target on Amarin Corporation (NASDAQ: AMRN), saying Vascepa ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
